KLK10: A Protein with Potential as A Drug Target Or Biomarker

Target Name: KLK10

NCBI ID: G5655

KLK10

KLK10: A Protein with Potential as A Drug Target Or Biomarker

KLK10, also known as kallikrein 10 protein 12, is a protein that is expressed in various tissues throughout the body. It is a member of the kallikrein family of proteins, which are known for their ability to generate cross-links between proteins. KLK10 is unique in that it is expressed in the placenta, and it has been shown to play a role in the regulation of pregnancy outcomes.

Recent studies have suggested that KLK10 may be a drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This is because KLK10 has been shown to interact with a wide range of molecules, including transcription factors, signaling proteins, and cytokines. Additionally, KLK10 has been shown to be involved in the regulation of cellular processes that are important for disease development, such as cell migration, angiogenesis, and inflammation.

One potential mechanism by which KLK10 may be involved in cancer is by its role in cell signaling. KLK10 has been shown to interact with various signaling proteins, including TGF-β1, PDGF, and NF-kappa-B. These proteins are involved in the regulation of cell growth, differentiation, and survival, and have been implicated in the development and progression of many types of cancer. Additionally, KLK10 has been shown to play a role in the regulation of angiogenesis, which is the process by which new blood vessels are formed to supply oxygen and nutrients to tissues. This may contribute to the development of new blood-borne tumors.

Another potential mechanism by which KLK10 may be involved in neurodegenerative diseases is by its role in the regulation of cellular processes that are important for brain function. KLK10 has been shown to interact with various neurotransmitter receptors, including dopamine, serotonin, and GABA. These molecules are involved in the regulation of mood, appetite, and other physiological processes that are important for brain function. Additionally, KLK10 has been shown to play a role in the regulation of neuroinflammation, which is the process by which the brain becomes inflamed in response to the presence of harmful substances. This may contribute to the development and progression of neurodegenerative diseases.

In addition to its potential role in cancer and neurodegenerative diseases, KLK10 has also been suggested as a potential biomarker for these conditions. This is because the expression of KLK10 has been shown to be regulated by a wide range of factors, including genetics, hormones, and environmental factors. Additionally, KLK10 has been shown to be involved in the regulation of cellular processes that are important for disease diagnosis, such as the development of cancerous tumors or the progression of neurodegenerative diseases. This suggests that KLK10 may be a useful biomarker for the diagnosis and treatment of these conditions.

Overall, KLK10 is a unique and fascinating protein that has the potential to be a drug target or biomarker for a wide range of conditions. Its role in the regulation of cell signaling, angiogenesis, and inflammation, as well as its potential as a biomarker for cancer and neurodegenerative diseases, makes KLK10 an important area of research for scientists and clinicians alike. Further studies are needed to fully understand the mechanisms by which KLK10 functions and its potential as a drug or biomarker.

Protein Name: Kallikrein Related Peptidase 10

Functions: Has a tumor-suppressor role for NES1 in breast and prostate cancer

The "KLK10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KLK10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets